Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25779343 | 0.86 | ALDH1A1 (0.48) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL25779336 | 0.83 | MEN1 (0.42) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL29892792 | 0.82 | EPHX2 (0.33) | MEN1KMT2ATSHRALDH1A1CYP4F2 | |
| SCHEMBL22890965 | 0.81 | TSHR (0.55) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL9317960 | 0.81 | LMNA (0.38) | MEN1KMT2ATHRBTSHRALDH1A1 | |
| SCHEMBL25779354 | 0.81 | MEN1 (0.39) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL491121 | 0.80 | MEN1 (0.52) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL11245006 | 0.79 | LMNA (0.40) | MEN1KMT2ATHRBTSHRALDH1A1 | |
| Di(Hydroxyethyl)Ether SCHEMBL4830560 | 0.79 | ALDH1A1 (0.50) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL29521238 | 0.79 | MEN1 (0.57) | MEN1KMT2ATHRBHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139745-A1 | NON-PEPTIDIC POLYMERIC LINKER COMPOUND, CONJUGATE COMPRISING SAME LINKER COMPOUND, AND METHODS FOR PREPARING SAME LINKER COMPOUND AND CONJUGATE | HANMI PHARM. CO., LTD. (KR) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139745-A1 | NON-PEPTIDIC POLYMERIC LINKER COMPOUND, CONJUGATE COMPRISING SAME LINKER COMPOUND, AND METHODS FOR PREPARING SAME LINKER COMPOUND AND CONJUGATE | FCGR1A, FCGR3B, FCGR2A | MEN1 981/4885KMT2A 3032/4885THRB 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.